Overview
- In the Phase 2b KEYNOTE-942 study, intismeran autogene plus Keytruda maintained a 49% reduction in recurrence or death at five years versus Keytruda alone after surgical resection of high-risk melanoma.
- Safety remained consistent with earlier readouts, with no new signals reported and common effects including fatigue, injection-site pain and chills.
- The adjuvant melanoma Phase 3 trial (INTerpath-001) has completed enrollment, and additional Phase 2/3 studies in lung, bladder and renal cancers are ongoing.
- Moderna and Merck plan to present further follow-up analyses at an upcoming medical meeting, and peer-reviewed details have not yet been published.
- The Phase 2b cohort previously included about 157 patients, and market reports say Moderna shares rose to a new 52-week high following the update.